Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 4, 2010, Pages 742-748

  Mulvihill, Erin E ^a,b   Assini, Julia M ^a,b   Sutherland, Brian G ^a   Dimattia, Alessandra S ^a   Khami, Maryam ^a   Koppes, Julie B ^a   Sawyez, Cynthia G ^a,b   Whitman, Stewart C ^c   Huff, Murray W ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Atherosclerosis; Hyperlipidemia; Insulin resistance; Naringenin; Obesity

Indexed keywords

CHOLESTEROL; FATTY ACID; GLUCOSE; GLYCEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; NARINGENIN; ANTILIPEMIC AGENT; FLAVANONE DERIVATIVE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HISTOLOGY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT GAIN; ANIMAL; AORTA; AORTA DISEASE; ATHEROGENIC DIET; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; FAT INTAKE; FATTY LIVER; GENETICS; HYPERINSULINISM; METABOLISM; MOUSE MUTANT; OBESITY; PATHOLOGY; TIME;

ANIMALS; ANTILIPEMIC AGENTS; AORTA; AORTIC DISEASES; ATHEROSCLEROSIS; CHOLESTEROL; DIET, ATHEROGENIC; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; FLAVANONES; HYPERINSULINISM; HYPERLIPIDEMIAS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; RECEPTORS, LDL; TIME FACTORS; TRIGLYCERIDES;

EID: 77950914240     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.201095     Document Type: Article

References (52)

1. Breslow JL. Cardiovascular disease burden increases NIH funding decreases. Nat Med. 1997. 3. 600-601.
2. St Clair RW, Yancey PG, Leight MA. Macrophage cholesterol balance: a potential site of genetic control of susceptibility to atherosclerosis. Ann N Y Acad Sci. 1995;748:264-275; discussion, 275-276.
3. Veniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, Hellerstein MK, Rudel LL, Walzem RL, Young SG. Defining the athero-genicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest. 2000;106:1501-1510.
4. Consigny PM. Pathogenesis of atherosclerosis. AJR Am J Roentgenol. 1995;164:553-558.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
6. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006;26:1702-1711.
7. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for pro-teoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007;117:94-98.
8. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Lipoproteins of special significance in atherosclerosis: insights provided by studies of type III hyperlipoproteinemia. Ann N Y Acad Sci. 1985;454:209-221.
9. Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation. 1999;99:2852-2854.
10. Joy T, Lahiry P, Pollex RL, Hegele RA. Genetics of metabolic syndrome. Curr Diab Rep. 2008;8:141-148.
11. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
12. Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008;102: 1040-1045.
13. Ginsberg HN. Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006;91: 383-392.
14. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225-1236.
15. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006;49:755-765.
16. Watts GF, Ooi EM, Chan DC. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol Ther. 2009;123: 281-291.
17. Feskens EJ, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease: the Zutphen Elderly Study. Arterioscler Thromb. 1994;14: 1641-1647.
18. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342:1007-1011.
19. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem Pharmacol. 1989;38: 1763-1769.
20. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr. 1995;61:549-554.
21. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344-1351.
22. Lee SH, Park YB, Bae KH, Bok SH, Kwon YK, Lee ES, Choi MS. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase in rats. Ann Nutr Metab. 1999;43:173-180.
23. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepato-cytes. Diabetes. 2005;54:1676-1683.
24. Allister EM, Mulvihill EE, Barrett PH, Edwards JY, Carter LP, Huff MW. Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor. J Lipid Res. 2008;49:2218-2229.
25. Borradaile NM, de Dreu LE, Huff MW. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes. 2003;52:2554-2561.
26. Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes. 2009;58:2198-2210.
27. Feng M, DiPetrillo K. Non-invasive blood pressure measurement in mice. Methods Mol Biol. 2009;573:45-55.
28. Covey SD, Krieger M, Wang W, Penman M, Trigatti BL. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler Thromb Vasc Biol. 2003;23:1589-1594.
29. Telford DE, Lipson SM, Barrett PH, Sutherland BG, Edwards JY, Aebi JD, Dehmlow H, Morand OH, Huff MW. A novel inhibitor of oxidos-qualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content. Arterioscler Thromb Vasc Biol. 2005;25:2608-2614.
30. Rogers L, Burchat S, Gage J, Hasu M, Thabet M, Willcox L, Ramsamy TA, Whitman SC. Deficiency of invariant Va14 natural killer T cells decreases atherosclerosis in LDL receptor null mice. Cardiovasc Res. 2008;78:167-174.
31. Li J, Han X, Jiang J, Zhong R, Williams GM, Pickering JG, Chow LH. Vascular smooth muscle cells of recipient origin mediate intimal expansion after aortic allotransplantation in mice. Am J Pathol. 2001; 158:1943-1947.
32. Merat S, Casanada F, Sutphin M, Palinski W, Reaven PD. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler Thromb Vasc Biol. 1999; 19:1223-1230.
33. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW; American Heart Association. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1512-1531.
34. Getz GS, Reardon CA. Diet and murine atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:242-249.
35. VanderLaan PA, Reardon CA, Thisted RA, Getz GS. VLDL best predicts aortic root atherosclerosis in LDL receptor deficient mice. J Lipid Res. 2009;50:376-385.
36. Teupser D, Persky AD, Breslow JL. Induction of atherosclerosis by low-fat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement). Arterioscler Thromb Vasc Biol. 2003;23:1907-1913.
37. Lee RG, Kelley KL, Sawyer JK, Farese RV Jr, Parks JS, Rudel LL. Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ Res. 2004;95:998-1004.
38. Rudel LL, Haines J, Sawyer JK, Shah R, Wilson MS, Carr TP. Hepatic origin of cholesteryl oleate in coronary artery atherosclerosis in African green monkeys: enrichment by dietary monounsaturated fat. J Clin Invest. 1997;100:74-83.
39. Bell TA III, Brown JM, Graham MJ, Lemonidis KM, Crooke RM, Rudel LL. Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor\/\mice. Arterioscler Thromb Vasc Biol. 2006;26:1814-1820.
40. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol. 1997;17:1337-1345.
41. Proctor SD, Mamo JC. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall: evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest. 1998;28:497-503.
42. Tobias P, Curtiss LK. Thematic review series: the immune system and atherogenesis: paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res. 2005;46:404-411.
43. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
44. Schreyer SA, Wilson DL, LeBoeuf RC. C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis. 1998; 136:17-24.
45. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamada N. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem. 2001;276:37402-37408.
46. Gruen ML, Saraswathi V, Nuotio-Antar AM, Plummer MR, Coenen KR, Hasty AH. Plasma insulin levels predict atherosclerotic lesion burden in obese hyperlipidemic mice. Atherosclerosis. 2006;186:54-64.
47. Senokuchi T, Liang CP, Seimon TA, Han S, Matsumoto M, Banks AS, Paik JH, DePinho RA, Accili D, Tabas I, Tall AR. Forkhead transcription factors (FoxOs) promote apoptosis of insulin-resistant macrophages during cholesterol-induced endoplasmic reticulum stress. Diabetes. 2008; 57:2967-2976.
48. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1-19.
49. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7:95-96.
50. Han S, Liang CP, Westerterp M, Senokuchi T, Welch CL, Wang Q, Matsumoto M, Accili D, Tall AR. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J Clin Invest. 2009;119: 1029-1041.
51. Subramanian S, Han CY, Chiba T, McMillen TS, Wang SA, Haw A III, Kirk EA, O'Brien KD, Chait A. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28: 685-691.
52. Aviram M, Volkova N, Coleman R, Dreher M, Reddy MK, Ferreira D, Rosenblat M. Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro in cultured macrophages and lipoproteins. J Agric Food Chem. 2008;56:1148-1157.